Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

Fineline Cube Mar 2, 2026
Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Fineline Cube Mar 2, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Imposes Sanctions on Six Firms Over Collusion in Bromhexine Bidding

Fineline Cube Aug 21, 2024

BEIJING—The National Drug Alliance Procurement Office, which oversees the Volume-Based Procurement (VBP) program, has announced...

Company Medical Device

MicroPort MedTech’s ReeAmber Catheter Wins NMPA Nod for Peripheral Artery Treatments

Fineline Cube Aug 20, 2024

SHANGHAI—Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical device...

Company

CGP’s 2024 Interim Report Shows Robust Growth in Revenues and Profits, Highlighting R&D Focus

Fineline Cube Aug 20, 2024

HONG KONG—China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has released its interim...

Company

Genmab CEO Signals Potential for China Partnership as BioNTech Exits acasunlimab Collaboration

Fineline Cube Aug 20, 2024

COPENHAGEN—In a strategic pivot following BioNTech (NASDAQ: BNTX)’s withdrawal from their co-development partnership on the...

Company Drug

Hasten Biopharmaceutical Gains NMPA Nod for Somatostatin Marketing Rights in China

Fineline Cube Aug 20, 2024

BEIJING—Hasten Biopharmaceutical Co., Ltd, a biopharmaceutical company supported by the CBC Group, has received approval...

Company Drug

Yipinhong Pharmacy’s AR882 Earns FDA Fast-Track Status for Gout Treatment

Fineline Cube Aug 20, 2024

BEIJING—China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced that its novel drug AR882 has...

Company Deals

Sichuan Kelun Pharmaceutical’s H1 2024 Report Highlights MSD Collaboration Milestones

Fineline Cube Aug 20, 2024

CHENGDU—Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has released its financial report for the first...

Policy / Regulatory

NHSA Flags Concerns Over Pricing of MicroPort’s Castor Aortic Stent Graft System

Fineline Cube Aug 20, 2024

BEIJING—The National Healthcare Security Administration (NHSA) has issued an open letter expressing concerns over the...

Company Drug

Astellas Pharma’s Padcev Receives NMPA Approval for Urothelial Cancer Treatment

Fineline Cube Aug 20, 2024

TOKYO—Astellas Pharma Inc. (TYO: 4503) has announced that its anti-HER3 antibody-drug conjugate (ADC), Padcev (enfortumab...

Company Drug

BioNTech’s BNT326/YL202 Clears FDA Hurdle, Advancing in Clinical Trials for Solid Tumor Treatment

Fineline Cube Aug 20, 2024

FRANKFURT—BioNTech SE (NASDAQ: BNTX), a leading German biotechnology company, has announced that the US Food...

Company Deals

Jiangsu Hengrui Pharmaceuticals Expands R&D Footprint with Jinan Innovation Zone Partnership

Fineline Cube Aug 20, 2024

JINAN—The management committee of the Jinan Innovation Zone has entered into a strategic partnership with...

Company Medical Device

China’s NMPA Grants Medical Device License to DaAn Gene’s Monkeypox Detection Kit

Fineline Cube Aug 20, 2024

GUANGZHOU—DaAn Gene Co., Ltd, a subsidiary of Sun Yat-sen University based in China (SHE: 002030),...

Company Deals

Genesis MedTech’s J-VALVE System Transfers to Edwards Lifesciences, Marking a New Era in Aortic Valve Treatment

Fineline Cube Aug 20, 2024

SINGAPORE—In a strategic move to strengthen its position in the global medical device market, Edwards...

Company Drug

Changchun High & New Technology Secures NMPA Approval for Turner Syndrome Treatment

Fineline Cube Aug 20, 2024

CHANGCHUN—Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading biopharmaceutical company in...

Company Drug

AstraZeneca’s Fasenra Secures NMPA Approval for Severe Eosinophilic Asthma Maintenance Therapy

Fineline Cube Aug 20, 2024

BEIJING—The National Medical Products Administration (NMPA) of China has granted market approval for AstraZeneca (NASDAQ:...

Company Drug

Genmab’s Tepkinly/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments

Fineline Cube Aug 20, 2024

COPENHAGEN—Genmab A/S (NASDAQ: GMAB), a leading biotech company, has announced that the European Commission (EC)...

Company Deals

Multitude Therapeutics and Adcendo ApS Partner on Anti-TF ADC, Targeting Global Cancer Treatment

Fineline Cube Aug 20, 2024

SHANGHAI/COPENHAGEN—In a strategic move to bolster cancer treatment options, Shanghai-based medical technology company Multitude Therapeutics...

Company Medical Device

Lepu Medical Secures Approval for RECATCHOR Catheter, Enhancing Cardiovascular Procedures

Fineline Cube Aug 19, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...

Drug Policy / Regulatory

Beijing Proposes New Regulations to Enhance Pharmaceutical Retail Standards and Services

Fineline Cube Aug 19, 2024

The Beijing Municipal Medical Products Administration has unveiled a draft proposal titled “Guiding Opinions on...

Company Drug

AstraZeneca’s Imfinzi Gains FDA Approval for Neoadjuvant Use in Early-Stage Lung Cancer

Fineline Cube Aug 19, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN) , the UK-based pharmaceutical powerhouse, has secured US FDA approval...

Posts pagination

1 … 274 275 276 … 628

Recent updates

  • Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug
  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
  • Sino Biopharma’s Rovadicitinib Wins NMPA Approval – First‑in‑Class JAK/ROCK Inhibitor for Myelofibrosis
  • Antengene’s XPOVIO Secures Second South Korea Reimbursement – Selinexor Combo Approved for Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Company Drug

InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label

Company Drug

Sino Biopharma’s Rovadicitinib Wins NMPA Approval – First‑in‑Class JAK/ROCK Inhibitor for Myelofibrosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.